

# An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans

Mardinoglu, Adil

2018-03-06

---

Mardinoglu , A , Wu , H , Bjornson , E , Zhang , C , Hakkarainen , A , Rasanen , S M , Lee , S , Mancina , R M , Bergentall , M , Pietilainen , K H , Soderlund , S , Matikainen , N , Stahlman , M , Bergh , P-O , Adiels , M , Piening , B D , Graner , M , Lundbom , N , Williams , K J , Romeo , S , Nielsen , J , Snyder , M , Uhlen , M , Bergstrom , G , Perkins , R , Marschall , H-U , Backhed , F , Taskinen , M-R & Boren , J 2018 , ' An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans ' Cell Metabolism , vol 27 , no. 3 , pp. 559-+ . DOI: 10.1016/j.cmet.2018.01.005

---

<http://hdl.handle.net/10138/233915>

<https://doi.org/10.1016/j.cmet.2018.01.005>

---

*Downloaded from Helda, University of Helsinki institutional repository.*

*This is an electronic reprint of the original article.*

*This reprint may differ from the original in pagination and typographic detail.*


*Please cite the original version.*

# Cell Metabolism

Clinical and Translational Report

## An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans

### Graphical Abstract



### Authors

Adil Mardinoglu, Hao Wu,  
Elias Björnson, ..., Fredrik Bäckhed,  
Marja-Riitta Taskinen, Jan Borén

### Correspondence

fredrik.backhed@wlab.gu.se (F.B.),  
jan.boren@wlab.gu.se (J.B.)

### In Brief

Mardinoglu et al. use multi-omics to investigate the effects of a carbohydrate-restricted diet in obese NAFLD patients. They show that the diet improves liver fat metabolism, promotes rapid shifts in the gut microbiota, increases circulating folate, and upregulates expression of genes involved in folate-dependent one-carbon metabolism in the liver.

### Highlights

- A low-carbohydrate diet (LCD) improves liver fat metabolism in NAFLD patients
- The LCD promotes rapid shifts in the gut microbiota composition of NAFLD patients
- The LCD-induced microbial changes are associated with increased circulating folate
- The LCD increases folate-dependent one-carbon metabolism gene expression in liver



# An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans

Adil Mardinoglu,<sup>1,2,8</sup> Hao Wu,<sup>3,8</sup> Elias Bjornson,<sup>2,3</sup> Cheng Zhang,<sup>1</sup> Antti Hakkarainen,<sup>4</sup> Sari M. Räsänen,<sup>5</sup> Sunjae Lee,<sup>1</sup> Rosellina M. Mancina,<sup>3</sup> Mattias Bergentall,<sup>3</sup> Kirsi H. Pietiläinen,<sup>5,6</sup> Sanni Söderlund,<sup>5</sup> Niina Matikainen,<sup>5,6</sup> Marcus Ståhlman,<sup>3</sup> Per-Olof Bergh,<sup>3</sup> Martin Adiels,<sup>3</sup> Brian D. Piening,<sup>7</sup> Marit Granér,<sup>5</sup> Nina Lundbom,<sup>4</sup> Kevin J. Williams,<sup>3</sup> Stefano Romeo,<sup>3</sup> Jens Nielsen,<sup>2</sup> Michael Snyder,<sup>7</sup> Mathias Uhlén,<sup>1</sup> Göran Bergström,<sup>3</sup> Rosie Perkins,<sup>3</sup> Hanns-Ulrich Marschall,<sup>3</sup> Fredrik Bäckhed,<sup>3,\*</sup> Marja-Riitta Taskinen,<sup>5</sup> and Jan Borén<sup>3,9,\*</sup>

<sup>1</sup>Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden

<sup>2</sup>Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden

<sup>3</sup>Department of Molecular and Clinical Medicine, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden

<sup>4</sup>HUS Medical Imaging Center, Radiology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland

<sup>5</sup>Research Programs Unit, Diabetes and Obesity, University of Helsinki and Department of Internal Medicine, Helsinki University Hospital, Helsinki, Finland

<sup>6</sup>Endocrinology, Abdominal Center, Helsinki University Hospital, Helsinki, Finland

<sup>7</sup>Department of Genetics, Stanford University, Stanford, CA 94305, USA

<sup>8</sup>These authors contributed equally

<sup>9</sup>Lead Contact

\*Correspondence: fredrik.backhed@wlab.gu.se (F.B.), jan.boren@wlab.gu.se (J.B.)

<https://doi.org/10.1016/j.cmet.2018.01.005>

## SUMMARY

A carbohydrate-restricted diet is a widely recommended intervention for non-alcoholic fatty liver disease (NAFLD), but a systematic perspective on the multiple benefits of this diet is lacking. Here, we performed a short-term intervention with an isocaloric low-carbohydrate diet with increased protein content in obese subjects with NAFLD and characterized the resulting alterations in metabolism and the gut microbiota using a multi-omics approach. We observed rapid and dramatic reductions of liver fat and other cardiometabolic risk factors paralleled by (1) marked decreases in hepatic *de novo* lipogenesis; (2) large increases in serum β-hydroxybutyrate concentrations, reflecting increased mitochondrial β-oxidation; and (3) rapid increases in folate-producing *Streptococcus* and serum folate concentrations. Liver transcriptomic analysis on biopsy samples from a second cohort revealed downregulation of the fatty acid synthesis pathway and upregulation of folate-mediated one-carbon metabolism and fatty acid oxidation pathways. Our results highlight the potential of exploring diet-microbiota interactions for treating NAFLD.

## INTRODUCTION

In the past 30 years, we have seen a marked increase in non-alcoholic fatty liver disease (NAFLD), and it is now the most common cause of chronic liver disease in western countries

(Chalasani et al., 2012; Rinella and Sanyal, 2016). NAFLD can progress from simple steatosis to non-alcoholic steatohepatitis (NASH), which is characterized by the additional presence of an inflammatory infiltrate and hepatocellular injury with or without fibrosis (Chalasani et al., 2012; Rinella and Sanyal, 2016), and may further progress to cirrhosis, liver failure, and hepatocellular carcinoma (Marengo et al., 2016). Increasing evidence also indicates that NAFLD is a significant independent risk factor for cardiovascular disease and type 2 diabetes (Lonardo et al., 2015; Targher et al., 2016), and the dyslipidemia that is present in many individuals with NAFLD potentially contributes to the link between these diseases (Gaggini et al., 2013).

The pathophysiology of NAFLD has not been resolved, but it develops when the influx of lipids into the liver exceeds hepatic lipid disposal (by fatty acid oxidation and triglyceride secretion as lipoprotein particles) (Stefan et al., 2008). Potential sources of lipids contributing to fatty liver include fatty acids released into the circulation from peripheral adipose tissue, dietary fatty acids from intestinal chylomicrons, and lipids synthesized (mostly from carbohydrates) in the liver by *de novo* lipogenesis (DNL) (Donnelly et al., 2005). In hyperinsulinemic subjects with NAFLD, hepatic DNL accounts for approximately 25% of liver triglyceride content (Diraison et al., 2003; Donnelly et al., 2005); thus, carbohydrate restriction, combined with exercise and regular follow-up, has emerged as an effective dietary intervention for obesity (Astrup et al., 2004; Foster et al., 2003) and NAFLD (Rinella and Sanyal, 2016). In addition to their effects on liver fat, carbohydrate-restricted diets have been shown to promote marked shifts in the composition of the gut microbiota (David et al., 2014; Duncan et al., 2007). Furthermore, accumulating evidence suggests that microbial changes are implicated in the development and progression of NAFLD (Le Roy et al., 2013; Leung et al., 2016; Loomba et al., 2017), and fecal microbiota transplantation has been shown to be



able to alleviate high-fat-induced steatohepatitis in mice (Zhou et al., 2017).

A systematic perspective integrating dietary intervention, microbial profiling, and in-depth metabolic characterizations in humans with NAFLD is lacking. Given the complexity of NAFLD pathogenesis, in-depth multi-omics profiling—an approach that has recently been used in studies of both human wellness and disease (Chen et al., 2012; Price et al., 2017; Wu et al., 2015)—would likely offer valuable insights into understanding how a carbohydrate-restricted diet promotes reduced hepatic steatosis. Here we performed a 2-week intervention with an isocaloric carbohydrate-restricted diet in obese subjects with NAFLD and used multi-omics profiling to investigate how the diet and associated changes in the gut microbiota contribute to improved liver fat metabolism. In addition, we combined plasma metabolomics and liver transcriptomics in a genome-scale metabolic model to further investigate the metabolic responses to this diet intervention.

## RESULTS AND DISCUSSION

### Reduced Carbohydrate Consumption Has Rapid Effects on Liver Fat

Earlier studies designed to reduce hepatic steatosis in subjects with NAFLD have usually combined carbohydrate restriction with calorie reduction and did not separate out the effect of amplified weight loss (Browning et al., 2006, 2011). To investigate how liver fat metabolism is affected by reduced carbohydrate consumption without a concomitant reduction in calorie intake, we served a pre-prepared isocaloric low-carbohydrate diet with increased protein content (<30 g of carbohydrates and an average of 3,115 kcal per day; Figure 1A; Table S1) for 14 days to ten subjects with obesity and high liver fat (mean  $\pm$  SEM 16.0%  $\pm$  2.3%). The study design is shown in Figure 1B. To minimize the weight loss that is known to occur on a short-term isocaloric carbohydrate-restricted diet (Kekwick and Pawan, 1956), the study subjects were in daily contact with a dietician and were instructed to increase their daily energy intake whenever their weight decreased between two study days by more than 0.2 kg.

There were no changes in waist circumference during the study (Table S1). Despite good compliance, we observed a slight weight loss (1.8%  $\pm$  0.2% of their body weight; Figure 1C). Body composition analysis at baseline and after 14 days on the diet revealed that decreases in fat mass and water were the major contributors to this minor weight loss (Figure 1D). In contrast to the small reduction in weight loss, we observed dramatic reductions in liver fat, as measured by magnetic resonance spectroscopy (MRS), in all the individuals over the 14-day study period (mean reduction 43.8%; Figure 1E). Of note, the reduction was significant just 1 day after the start of the diet intervention ( $p = 0.027$ ) and was paralleled by a significant decrease in total liver volume (Figure S1).

We observed marked reductions in very-low-density lipoprotein (VLDL)-triglycerides (mean reduction 56.7%; Figure 1F) and in fasting plasma triglyceride concentrations (mean reduction 48.4%; Table S1) at the end of the study. In addition, we found a significant reduction of plasma apolipoprotein C-III (apoC-III) (Figure 1G), an inhibitor of VLDL clearance (Ginsberg et al.,


1986) and a strong correlation between decreases in the concentration of apoC-III and VLDL-triglycerides over the study period ( $r = 0.91$ ,  $p = 0.0015$ ; Figure S2). We also analyzed the composition of VLDL-triglycerides and observed a decreased proportion of saturated fatty acids including myristic acid (14:0) and palmitic acid (16:0) and an increased proportion of unsaturated fatty acids such as oleic acid (18:1) (Table S1). These data are consistent with a significant increase in the number of double bonds per fatty acid chain observed by MRS of the liver over the study period (Table S1).

To test whether the marked reductions in liver fat were linked to the diet intervention, we performed a follow-up MRS in seven of the ten participants 1–3 months after completing the intervention study and returning to their normal diet. We observed that their liver fat content returned to a level similar to that measured before the diet intervention (11.3%  $\pm$  1.6% at follow-up versus 13.8%  $\pm$  2.5% at baseline,  $p = 0.08$ ).

### Reduced Carbohydrate Consumption Improves Liver Fat Metabolism

To investigate the effects of the diet on processes linked to fat accumulation in the liver, we measured DNL using stable isotope technology and  $\beta$ -hydroxybutyrate (a proxy for  $\beta$ -oxidation). We observed a rapid and dramatic reduction in absolute DNL (Figure 1H), which was paralleled by a rapid increase in hepatic  $\beta$ -oxidation (Figure 1I). At the end of the 14-day diet intervention, DNL was 79.8% lower and  $\beta$ -hydroxybutyrate was 4.9-fold higher than at baseline (Figures 1H and 1I). However, there was no significant change in plasma non-esterified fatty acid (NEFA) concentrations over the study period (Table S1). Furthermore, there was a strong correlation between the reductions in DNL and liver fat ( $r = 0.96$ ,  $p = 0.0001$ ) and a trend toward a significant correlation between the reductions in DNL and VLDL-triglycerides ( $r = 0.67$ ,  $p = 0.07$ ) (Figure S2). Consistent with improvements in liver function and metabolism, we observed significant reductions in fasting plasma concentrations of alkaline phosphatase and aspartate transaminase, markers of liver damage, as well as significant decreases in fasting insulin and HOMA-IR (homeostasis model assessment of insulin resistance) values over the study period (Table S1).

Studies characterizing the pathogenesis of NAFLD have focused overwhelmingly on the dysregulation of hepatic DNL (Chakravarthy et al., 2005; Fabbrini et al., 2010; Petersen et al., 2007; Wang et al., 2015) and increased delivery of NEFAs from adipose tissue to the liver especially in insulin-resistant subjects (Lewis et al., 2002); according to one estimation (Donnelly et al., 2005), these pathways account for 25% and 60% of liver fat, respectively. In contrast, the roles of the pathways involved in hepatic lipid disposal (i.e., mitochondrial  $\beta$ -oxidation and VLDL-triglyceride export) in NAFLD pathogenesis are less characterized. By restricting carbohydrate intake and thus blunting DNL, we observed a dramatic reduction of liver fat paralleled by a rapid increase of mitochondrial  $\beta$ -oxidation and a marked reduction of VLDL-triglycerides without any change in plasma NEFA concentrations. Thus, the reduced hepatic lipid accumulation could be explained by both blunted DNL and enhanced mitochondrial  $\beta$ -oxidation; however, as their regulation is tightly connected (McGarry et al., 1977) it is difficult to estimate the relative contribution of these two sources in our study.



**Figure 1. Reduced Carbohydrate Consumption Improves Liver Lipid Metabolism and Reduces Inflammation in Obese Subjects with NAFLD**

(A) Percentage of energy from carbohydrate, protein, and fat at baseline (inner circle) and during the 14-day dietary intervention (outer circle).

(B) Study design indicating time points used in the multi-omics analysis. D, day.

(C–E) Boxplots (with median) and individual data showing (C) weight changes across the study period, (D) changes in body composition between day 0 and day 14, and (E) liver fat changes across the study period.

(F–I) Boxplots (with median) showing (F) plasma concentrations of VLDL-triglycerides (TG) (n = 10), (G) plasma concentrations of apoC-III (n = 10), (H) DNL (n = 9), and (I) plasma concentrations of  $\beta$ -hydroxybutyrate (n = 10) at days 0, 3, and 14.

(J) Heatmap showing statistically significant reductions in inflammatory markers and FGF-21 over the study period (FDR < 0.05; n = 10). Post hoc group comparisons (D0 versus D3 and D0 versus D14) were performed by paired t test with Bonferroni correction. \* $p < 0.05$ ; \*\* $p < 0.01$ ; # $p < 0.001$ . p or FDR values across time were obtained by one-way ANOVA with repeated measurements.

See also Figures S1 and S2 and Table S1.

## Reduced Carbohydrate Consumption Decreases Inflammatory Markers and FGF21

NAFLD has been linked to a low-grade systemic inflammation (Asrih and Jornayaz, 2013; Brauwersreuther et al., 2012), and high carbohydrate intake has been shown to associate with higher inflammation (Solga et al., 2004). We therefore investigated the effect of the dietary intervention on a range of inflammation-related plasma proteins. We observed significant reductions in many of the inflammatory markers over the study period (Figure 1J). In particular, we showed that plasma concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF- $\alpha$ ) were significantly reduced after 14 days of the carbohydrate-restricted diet (Figure 1J). IL-6 and TNF- $\alpha$  have attracted particular attention because the severity of NAFLD and progression to NASH are associated with higher systemic levels of these cytokines (Paredes-Turribiarte et al., 2016; Wieckowska et al., 2008). However, we did not observe significant reductions in these cytokines after 3 days on the diet, indicating that they are not the main drivers of liver fat.

Several studies have shown that concentrations of the peptide hormone fibroblast growth factor 21 (FGF21) are elevated in subjects with NAFLD and correlate with hepatic fat content (Dushay et al., 2010; Li et al., 2010), and plasma FGF21 has been suggested as a potential diagnostic marker of NAFLD (Li et al., 2013). Consistent with these findings, we showed that plasma concentrations of FGF21 decreased rapidly in response to the carbohydrate-restricted diet, with significant reductions after both 3 and 14 days on the diet (Figure 1J). Paradoxically, plasma FGF21 concentrations in rodents increase in response to low-carbohydrate ketogenic diets (Badman et al., 2007, 2009; Laeger et al., 2014). One potential explanation for this difference is that FGF21 expression in rodents has been shown to be sensitive to the protein content of the diet (Laeger et al., 2014). Ketogenic diets given to rodents typically contain reduced protein levels compared with control diet, in contrast to our study diet with increased protein content. An earlier study also reported diet-induced reductions in FGF21 concentrations in humans upon increased protein intake (Christodoulides et al., 2009). Moreover, plasma concentrations of FGF21 are increased in individuals who have undergone bariatric surgery (Lips et al., 2014), a treatment that is commonly associated with protein malnutrition (Bal et al., 2012). We therefore speculate that the protein content in the diet plays important roles in regulating human FGF21 expression.

## Reduced Carbohydrate Consumption Induces Rapid Shifts in the Gut Microbiota Composition


Because of the increasing evidence supporting a link between diet, the gut microbiota, and NAFLD (Leung et al., 2016), we investigated how the gut microbiome was affected by the dietary intervention. We performed whole-genome shotgun sequencing of fecal samples obtained from the participants at five time points across the study (0, 1, 3, 7, and 14 days). On average, we obtained 17.5 million paired-end reads for each sample (ranging from 14.2 million to 21.3 million; Table S2). Ninety-four bacterial strains were significantly altered upon dietary intervention (Figure 2A; Table S2), and major shifts occurred after only 1 day of the dietary intervention (Figure 2A). Principal coordinate analysis (PCoA) of the relative abundance of all these signifi-

cantly altered strains confirmed the dramatic compositional shifts of the gut microbiome after 1 day (Adonis test;  $p = 0.049$ ; Figure 2B). These observations are consistent with earlier studies that reported rapid alterations in both microbial composition (David et al., 2014; Wu et al., 2011) and bacterial growth rate (Korem et al., 2015) in response to extreme dietary interventions. We observed further compositional shifts after 7 days, but not between 7 and 14 days (Figure 2B), suggesting that the compositional shifts stabilized after 1 week on the low-carbohydrate diet with increased protein content. Among the top ten most abundant of 25 significantly altered genera, only *Streptococcus*, *Lactococcus*, and *Eggerthella* were increased over the study period (Figure 2C; Table S2). The carbohydrate-degrading bacteria *Ruminococcus*, *Eubacterium*, *Clostridium*, and *Bifidobacterium* were all decreased (Figure 2C; Table S2). In parallel, we observed decreased carbohydrate fermentation as shown by reductions in fecal concentrations of short-chain fatty acids (SCFAs) (Figure 2D), in agreement with previous studies (David et al., 2014; Duncan et al., 2007).

## Diet-Induced Functional Shifts in the Gut Microbiota Increase Folate Production

To further investigate functional changes in the gut microbiome in response to the dietary intervention, we annotated genes to KEGG orthology (KO) (Kanehisa and Goto, 2000). In total, 598 and 580 KOs were significantly increased and decreased, respectively, after 14 days on the diet (Figure 3S; Table S2). Pathway enrichment analysis demonstrated that these 1,178 KOs were involved in 18 KEGG pathways (Figure 3A). Of these, the most upregulated pathways were those involved in folate biosynthesis and the two-component system (which controls gene expression in response to changes in environmental conditions in many bacterial species), whereas the pathways involved in starch and sucrose metabolism and biosynthesis of amino acids including branched-chain amino acids (BCAAs; valine, leucine, and isoleucine) were significantly decreased (Figure 3A). Notably, the folate biosynthesis and starch and sucrose metabolism pathways were significantly altered after only 1 day of dietary intervention (Figure 3A). In-depth analysis of bacterial folate biosynthesis pathways showed that seven of 12 related KOs were significantly increased over the study period (Figure 3B). Of note, folate is a common food fermentation product during the growth of *Streptococcus* and *Lactococcus* (LeBlanc et al., 2011), and both of these lactic acid bacteria increased in abundance over the study period (Figure 2C).

Both the gut microbiota and the diet are sources of serum folate. Although folate is known to be present at higher levels in diets rich in carbohydrates (e.g., from vegetables and cereals) (Withköft et al., 1999), we did not observe any significant changes in dietary folate when the participants changed to the carbohydrate-restricted diet (Table S1). Furthermore, in contrast to previous studies that reported reduced or no significant changes in serum folate levels in response to carbohydrate-restricted diets (Keogh et al., 2008; Noakes et al., 2005; Nuttall and Gannon, 2006; Wycherley et al., 2010), we observed a significant increase in serum folate concentrations after just 1 day of the diet (Figure 3C;  $p = 0.0039$ ), in parallel with the rapid effect of the diet on liver fat (Figure 1E). This discrepancy between our study and earlier studies may be explained by differences



**Figure 2. Reduced Carbohydrate Consumption Rapidly Alters Gut Microbial Composition**

(A) Heatmap showing significant changes in the abundance of bacterial strains over the 14-day study period. D, day. FDR < 0.05; likelihood ratio test.

(B) PCoA plot based on the relative abundance of all bacterial strains that are significantly altered over the study period at the indicated time points (mean  $\pm$  SEM; p D1 versus D0 = 0.049; Adonis test based on 5 000 permutations).

(C) Boxplots (with median) showing the relative abundance of the ten most abundant genera that were significantly altered by the diet over the study period ( $n = 10$ ). FDR  $< 0.05$ ; likelihood ratio test.


(D) Boxplots (with median) showing fecal concentrations of SCFAs at days 0, 1, 3, 7, and 14 ( $n = 10$ ). p values across time were obtained by one-way ANOVA with repeated measurements.

Repeated measures  
See also Table 63

in the macronutrient composition. Our diet had both increased protein content compared with the baseline diet and very low carbohydrate content (<10% energy from carbohydrates). It is thus likely that the high dietary protein content combined with the reduction in carbohydrate-dependent bacteria would drive the growth of the folate-producing bacteria *Streptococcus* and *Lactococcus*, resulting in increased bacterial folate production. We also observed a trend toward an increase in fecal folate when the participants changed to the low-carbohydrate diet.

with increased protein content (Figure S4), suggesting that bacterially produced folate could contribute to the diet-induced increase in serum folate concentrations.

Our findings thus indicate that the increased circulating folate could be a consequence of the altered microbial composition. In support of this, previous studies have shown that the gut microbiota can produce large quantities of folate (Kim et al., 2004; Rossi et al., 2011; Strozzi and Mogna, 2008; Sugahara et al., 2015) and that folate is absorbable across the colon in



**Figure 3. Reduced Carbohydrate Consumption Promotes Microbial Shifts toward Folate Production**

(A) KEGG pathway analysis showing pathways that were significantly altered at the indicated times over the 14-day study period (n = 10). D, day. Pathways that are reduced or increased are shown in blue and brown, respectively. FDR < 0.1; hypergeometric test. The size of the bubble is proportional to the enrichment score for each KEGG pathway term.

(B) Bacterial folate biosynthesis pathway showing KOs that significantly increased over the study period (brown boxes).

(C) Boxplots (with median) showing changes in serum concentrations of folate changes over the study period (n = 10). p values across time were obtained by one-way ANOVA with repeated measurements. S, screen.

See also Figures S3 and S4 and Table S2.


humans (Aufreiter et al., 2009). We thus provide the first evidence indicating that a low-carbohydrate diet with increased protein content can shift the gut microbiota toward increased production of folate that is potentially utilized by humans. However, we cannot exclude the possibility that the carbohydrate-restricted diet promoted enhanced dietary folate absorption in the small intestine, resulting in increased circulating concentrations of folate and favoring the growth of bacteria that produce folate.

### Folate and Associated Metabolites Are Linked to Improved Liver Fat Metabolism

Animal studies have revealed that folate deficiency increases expression of pro-inflammatory cytokines such as IL-6 and TNF- $\alpha$  (Kolb and Petrie, 2013) and has detrimental effects on hepatic lipid metabolism (Akesson et al., 1982), leading to accumulation of liver fat (Kelley et al., 1950) and steatosis (Christensen et al., 2010; Halsted et al., 2002). Growing evidence also indicates a role for folate deficiency in the pathogenesis of NAFLD in humans (Hirsch et al., 2005; Xia et al., 2017). We therefore investigated whether serum folate correlated with liver fat in our study. We first performed a correlation

analysis between these two variables for each individual in the first cohort using data collected at seven time points across the study (0, 1, 3, 4, 7, 10, and 14 days). Despite the limited number of sampling points, we observed significant correlations in five of ten of these individuals and a trend toward significance in a further two (Figure 4A). No correlation between liver fat and serum folate was observed in three individuals (Figure 4A), two of whom had the lowest liver fat in the cohort at baseline (<10%); a lack of correlation in these two is likely explained by the fact that their liver fat had reduced to normal levels (<5%) by day 7 and thus plateaued (Figure 1E). However, by performing a partial regression analysis between liver fat and serum folate based on a linear mixed-effect model, we observed an overall significant association between liver fat and serum folate ( $p = 0.0001$ ); according to this model, serum folate could explain 35.4% and 19.5% of the variation in liver fat before and after adjusting for BMI, respectively (Figure 4B).

To investigate whether there are other metabolites that could potentially play a role in improved liver fat metabolism in our study, we also performed untargeted metabolomics on plasma samples from the participants at baseline and after 3 and 14 days on the dietary intervention. We observed significant



**Figure 4. Serum Folate Is Associated with Improved Liver Lipid Metabolism**

(A) Pearson correlations between liver fat and serum folate in each individual in the first cohort. D, day.

(B) Linear mixed-effect model (with 95% confidence bands highlighted) between liver fat and serum folate after adjusting for contributions from BMI to both variables; samples from the same individual are colored as in (A) ( $n = 10$ ).

(C) Integration of liver fat, folate-producing bacteria, serum folate, and metabolomics data from the first cohort ( $n = 10$ ) using a multivariate method (mixDIABLO with repeated measurements) with a correlation cutoff of 0.8. Components are linear combinations of variables from each omics dataset that are maximally correlated using a full-design matrix.

See also Figures S5 and S6 and Table S3.

changes in the relative signal intensity of 202 of 648 detected metabolites over the study period, most of which are involved in lipid or amino acid metabolism (Figure S5; Table S3). In particular, we observed significant decreases in metabolites involved in fatty acid synthesis (including those involved in phospholipid, lysolipid, and diacylglycerol metabolism). Circulating diacylglycerol concentrations have been repeatedly linked with insulin resistance (Petersen et al., 2017); thus, reductions in diacylglycerol are consistent with the improved insulin sensitivity observed in this study (Table S1). We also observed significant increases in metabolites involved in  $\beta$ -oxidation pathways and plasmalogens, which are known antioxidants (Wallner and Schmitz, 2011) (Figure S5; Table S3). Increased oxidative stress is considered to contribute to the pathogenesis of NAFLD (Haas et al., 2016), and antioxidants help to maintain the cellular redox balance by neutralizing the oxidative stress produced by fatty acid oxidation (Gambino et al., 2011), thereby alleviating NAFLD. Nicotinamide and its methylation product 1-methylnicotinamide, which has been shown to suppress liver triglyceride levels in mice (Hong et al., 2015), were also increased during the dietary intervention (Table S3).


By using multivariate dimension reduction and discriminant analysis, we revealed that 48 of the 202 significantly altered metabolites strongly correlated with serum folate (and thus liver fat) as well as with the folate-producing bacteria *Streptococcus* and *Lactococcus* (correlation coefficient cutoff 0.8; Figure 4C; Table S3). Of note,  $\beta$ -hydroxybutyrate and most of the identified plasmalogens associated with folate (Figure 4C; Table S3), suggesting that folate may improve liver fat metabolism by promoting an increase in mitochondrial  $\beta$ -oxidation and a reduction of oxidative stress. In agreement, previous studies have demonstrated that folate can confer protective effects against oxidative stress (Sid et al., 2017). However, further efforts are needed to explore the molecular and cellular mechanisms behind the multiple potential benefits provided by folate.

### Liver Transcriptional Changes Reflect Improved Lipid Metabolism

We also served the identical isocaloric low-carbohydrate diet with increased protein content to a second cohort of seven subjects for 7 days. In this second cohort of similar age ( $p = 0.379$ ) and BMI ( $p = 0.230$ ), we confirmed that the diet reduced DNL, fasting plasma triglycerides, plasma concentrations of alkaline phosphatase and insulin, and HOMA-IR values (Table S4). Analysis of liver biopsies taken from these subjects 7 days before the study start and after 7 days of dietary intervention showed that the diet significantly reduced the hepatic triglycerides by a mean of 43.9% (Table S4). Notably, we also observed a significant increase in serum folate concentrations in this cohort (Table S4).

To investigate whether alterations in hepatic gene expression reflected the diet-induced improvements in lipid metabolism, we also performed a global transcriptomic analysis on the liver samples collected from this second cohort. We observed significant decreases in 9.1% of genes, whereas only 3.8% of genes increased after 7 days on the diet (false discovery rate [FDR] adjusted  $p$  value  $< 0.1$ ; Table S5). KEGG pathway enrichment analysis revealed that 34 pathways were upregulated, including fatty acid degradation, amino acid metabolism, and peroxisome proliferator-activated receptor (PPAR) signaling pathways, whereas only seven pathways were downregulated, such as ribosome and oxidative phosphorylation (Table S5).

Consistent with the diet-induced reductions in plasma apoC-III concentrations and DNL noted earlier, we observed decreased hepatic expression of *APOC3* and *FASN* (although no significant changes in *SREBP-1c*) in the second cohort after 7 days on the diet (Table S5). We also observed diet-induced increases in the hepatic expression of PPAR- $\alpha$  and its downstream genes (Figure 5), most of which are known to encode proteins involved in the fatty acid oxidation including mitochondrial and peroxisomal  $\beta$ -oxidation as well as microsomal  $\omega$ -oxidation (Figure 5) (Kersten, 2014; Pawlak et al., 2015). Intriguingly, both the



**Figure 5. Liver Transcriptome Changes Reflect Improved Hepatic Lipid Metabolism**


Gene regulatory network for PPAR $\alpha$  showing significant increases (salmon) and decreases (light blue) in genes in liver from individuals in the second cohort after 7 days on a low-carbohydrate diet with increased protein content ( $n = 7$ ). FDR < 0.1; Wald test with paired design. See also Table S5.

gut microbiota (Crawford et al., 2009) and folate (Tryndyak et al., 2012) have been shown to be able to regulate hepatic lipid metabolism via a PPAR- $\alpha$ -regulated lipid catabolic pathway.

Expression of *CAT*, the gene encoding catalase, was also up-regulated in response to the diet (Table S5). Hepatic expression of the fatty acid transporter gene *CD36* was not significantly changed (Figure 5), in line with the lack of effect of the diet on plasma NEFA concentrations in both cohorts (Tables S1 and S4). Notably, consistent with the diet-induced increase in serum folate concentrations in both cohorts (Figure 3C; Table S4), we found diet-induced increases in the hepatic expression of genes involved in folate-mediated one-carbon metabolism, including

*MTRR*, *SHMT1*, *SHMT2*, *MTHFD1*, and *ALDH1L1* (Figure 6A), and the proton-coupled folate transporter gene *SLC46A1* (Table S5). Serine hydroxymethyltransferase (SHMT) catalyzes the interconversion of glycine and serine, and serine is required for the generation of glutathione (GSH), an antioxidant that also plays a role in maintaining  $\beta$ -oxidation (Mardinoglu et al., 2017; Nguyen et al., 2013). We have previously shown that individuals with NAFLD have serine deficiency (Mardinoglu et al., 2014, 2017) and that *de novo* GSH synthesis is altered in humans with hepatic steatosis (Mardinoglu et al., 2017).

Finally, we integrated the liver transcriptomics and plasma metabolomics data using *iHepatocytes2322*, a functional



**Figure 6. Integration of Liver Transcriptomics and Plasma Metabolomics Data**

(A) Reactions involved in folate-mediated one-carbon metabolism showing significant increases (red) and decreases (light blue) in genes in liver from individuals after 7 days on a low-carbohydrate diet with increased protein content ( $n = 7$ ). FDR < 0.1; Wald test with paired design.

(B) A genome-wide metabolic model for the liver integrating both serum metabolomics data and liver transcriptomics data. Red lines indicate increased fluxes, and blue lines indicate decreased fluxes.

See also Tables S5 and S6.

genome-scale metabolic model of hepatocytes (Mardinoglu et al., 2014). As expected, given the diet-induced reduction in DNL, the model predicted a significant reduction of fluxes carried by the reactions associated with glycolysis, the pentose phosphate pathway, and the tricarboxylic acid (TCA) cycle (Figure 6B; Table S6). The decreased fluxes in the reactions involved in glycolysis and the TCA cycle were partly compensated by increased fluxes in  $\beta$ -oxidation and BCAAs, required to provide sufficient energy as well as substrates for the biosynthesis of essential metabolites. Of note, we observed that the fluxes carried by the reactions involved in folate and methionine metabolism, serine uptake, as well as in the *de novo* synthesis of GSH were significantly increased in response to the diet. Our data are thus consistent with a central role of folate in mediating one-carbon metabolism and its involvement in a number of biosynthetic processes including synthesis of

glycine, serine, and methionine (Ducker and Rabinowitz, 2017; Sid et al., 2017).

### Study Limitations

There are several strengths with this study, but there are also limitations. For example, the study lacks a control group, in which a normal carbohydrate diet was provided to subjects. In addition, the types of carbohydrate, protein, and fat provided during the diet intervention were not matched with the diet the subjects consumed before the study. Therefore, it is possible that changes in the types of macronutrients (e.g., refined sugars versus complex carbohydrates, saturated versus unsaturated fats, plant versus animal proteins) could have affected the outcome measures.

### Conclusions

In summary, by using a multi-omics approach, we showed that short-term intervention with an isocaloric low-carbohydrate diet with increased protein content promotes multiple metabolic benefits in obese humans with NAFLD. In particular, we observed a dramatic reduction of liver fat resulting from a marked decrease in DNL and increase in  $\beta$ -oxidation. Of note, our data indicate that rapid microbial shifts toward folate production paralleled by increased circulating folate concentrations may be partially behind the improved lipid metabolism, balanced oxidative stress, and reduced inflammation. Taken together, these findings are of important clinical interest in understanding the pathogenesis and prevention of NAFLD. However, although studies in mice have shown that folate supplementation protects against high-fat-diet-induced liver steatosis (Sid et al., 2015, 2017), care should be taken before implementing folate supplementation into clinical practice since long-term effects remain to be elucidated.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Clinical Study Design
  - Isocaloric Carbohydrate-Restricted Diet
  - Influence of Gender
- **METHOD DETAILS**
  - Genotyping of *PNPLA3* and *TM6SF2* Variants
  - Body Composition, Liver Fat and Liver Volume
  - Measurement of Hepatic DNL
  - Lipoproteins and Biochemical Analyses
  - Fecal Genomic DNA and Genome Sequencing
  - Metagenomics Analyses
  - Measurement of Fecal SCFAs and Folate
  - Untargeted Metabolomics Analyses
  - Liver Lipid Analysis
  - Transcript Profiling of Liver Biopsies
  - Model Simulation
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Statistical Analysis

- DATA AND SOFTWARE AVAILABILITY
  - Datasets Generated and Deposited
- ADDITIONAL RESOURCES

## SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures and six tables and can be found with this article online at <https://doi.org/10.1016/j.cmet.2018.01.005>.

## ACKNOWLEDGMENTS

The authors thank Ara Koh for helpful discussions, Anna Hallén for preparation of the graphical abstract, all staff for excellent laboratory work and patient care, and the clinical biomarker facility at SciLifeLab, Sweden. Whole-genome shotgun sequencing was performed at the Genomics Core Facility at the Sahlgrenska Academy, University of Gothenburg. The computations for metagenomics analyses were performed on resources provided by the Swedish National Infrastructure for Computing (SNIC) through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX). This work was supported by grants from the Swedish Research Council, Swedish Heart-Lung Foundation, Swedish Diabetes Foundation, Sahlgrenska University Hospital ALF funds, Sigrid Jusélius Foundation, Academy of Finland, Finnish Diabetes Research Foundation, and EU Innovative Medicines Initiative EMIF, and by the FP7-HEALTH-2012-INNOVATION-1 program RESOLVE no. 305707. F.B. is a recipient of a European Research Council consolidator grant 615362 - METABASE and Torsten Söderberg Professor in Medicine.

## AUTHOR CONTRIBUTIONS

M.-R.T., H.-U.M., K.H.P., F.B., K.J.W., N.M., and S.S. were involved in study design. S.M.R., S.S., N.M., and M.G. were involved in clinical studies in the first cohort. A.H. and N.L. collected and analyzed the magnetic resonance data of the first cohort. H.-U.M. and G.B. were involved in clinical studies in the second cohort. A.M., C.Z., and S.L. performed the transcriptome pre-processing and integration with metabolomics data using GEM. E.B. performed the pre-processing of the inflammation markers. R.M.M. and S.R. performed genetic screening and helped with the metadata preparation. B.D.P., J.N., M. Snyder, M.A., and M.U. were involved in data analyses. H.W. conducted computational and statistical analyses as well as data visualization. M.B. assisted in metagenomic analysis. M. Ståhlman and P.-O.B. measured the fecal SCFA and folate and performed lipidomics analyses. H.W., R.P., and J.B. wrote the paper. Corresponding authors: F.B. is responsible for analyses related to the gut microbiome, and J.B. is responsible for all other parts of the study. All authors commented on the manuscript.

## DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: September 11, 2017

Revised: December 6, 2017

Accepted: January 10, 2018

Published: February 15, 2018

## REFERENCES

- Akesson, B., Fehling, C., Jagerstad, M., and Stenram, U. (1982). Effect of experimental folate deficiency on lipid metabolism in liver and brain. *Br. J. Nutr.* **47**, 505–520.
- Anders, S., and Huber, W. (2010). Differential expression analysis for sequence count data. *Genome Biol.* **11**, R106.
- Asrih, M., and Jornayaz, F.R. (2013). Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. *J. Endocrinol.* **218**, R25–R36.
- Astrup, A., Meinert Larsen, T., and Harper, A. (2004). Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? *Lancet* **364**, 897–899.
- Aufreiter, S., Gregory, J.F., 3rd, Pfeiffer, C.M., Fazili, Z., Kim, Y.I., Marcon, N., Kamalaporn, P., Pencharz, P.B., and O'Connor, D.L. (2009). Folate is absorbed across the colon of adults: evidence from cecal infusion of (13)C-labeled [6S]-5-formyltetrahydrofolic acid. *Am. J. Clin. Nutr.* **90**, 116–123.
- Badman, M.K., Kennedy, A.R., Adams, A.C., Pissios, P., and Maratos-Flier, E. (2009). A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss. *Am. J. Physiol. Endocrinol. Metab.* **297**, E1197–E1204.
- Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., and Maratos-Flier, E. (2007). Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. *Cell Metab.* **5**, 426–437.
- Bal, B.S., Finelli, F.C., Shope, T.R., and Koch, T.R. (2012). Nutritional deficiencies after bariatric surgery. *Nat. Rev. Endocrinol.* **8**, 544–556.
- Bartoń, K. (2016). MuMln: multi-model inference. R package, version 1.15.6. <https://CRAN.R-project.org/package=MuMln>.
- Bates, D., Mächler, M., Bolker, B., and Walker, S. (2015). Fitting linear mixed-effects models using lme4. *J. Stat. Software* **67**, <https://doi.org/10.18637/jss.v067.i01>.
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. Roy. Stat. Soc. B* **57**, 289–300.
- Bian, H., Hakkarainen, A., Lundbom, N., and Yki-Jarvinen, H. (2014). Effects of dietary interventions on liver volume in humans. *Obesity* **22**, 989–995.
- Braunersreuther, V., Viviani, G.L., Mach, F., and Montecucco, F. (2012). Role of cytokines and chemokines in non-alcoholic fatty liver disease. *World J. Gastroenterol.* **18**, 727–735.
- Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. *Nat. Biotechnol.* **34**, 525–527.
- Breheny, P., and Burchett, W. (2016). Visualization of regression models using visreg. Version 2.3.0. <https://CRAN.R-project.org/package=visreg>.
- Browning, J.D., Baker, J.A., Rogers, T., Davis, J., Satapati, S., and Burgess, S.C. (2011). Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. *Am. J. Clin. Nutr.* **93**, 1048–1052.
- Browning, J.D., Davis, J., Saboorian, M.H., and Burgess, S.C. (2006). A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content. *Hepatology* **44**, 487–488.
- Bugger, B., Erben, G., Sandhoff, R., Wieland, F.T., and Lehmann, W.D. (1997). Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry. *Proc. Natl. Acad. Sci. USA* **94**, 2339–2344.
- Chakravarthy, M.V., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J.G., Coleman, T., Turk, J., and Semenkovich, C.F. (2005). "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. *Cell Metab.* **1**, 309–322.
- Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., and Sanyal, A.J. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. *Am. J. Gastroenterol.* **107**, 811–826.
- Chen, R., Mias, G.I., Li-Pook-Than, J., Jiang, L., Lam, H.Y., Chen, R., Miriami, E., Karczewski, K.J., Hariharan, M., Dewey, F.E., et al. (2012). Personal omics profiling reveals dynamic molecular and medical phenotypes. *Cell* **148**, 1293–1307.
- Christensen, K.E., Wu, Q., Wang, X., Deng, L., Caudill, M.A., and Rozen, R. (2010). Steatosis in mice is associated with gender, folate intake, and expression of genes of one-carbon metabolism. *J. Nutr.* **140**, 1736–1741.
- Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., and Karpe, F. (2009). Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. *J. Clin. Endocrinol. Metab.* **94**, 3594–3601.

- Crawford, P.A., Crowley, J.R., Sambandam, N., Muegge, B.D., Costello, E.K., Hamady, M., Knight, R., and Gordon, J.I. (2009). Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation. *Proc. Natl. Acad. Sci. USA* **106**, 11276–11281.
- David, L.A., Maurice, C.F., Carmody, R.N., Gootenberg, D.B., Button, J.E., Wolfe, B.E., Ling, A.V., Devlin, A.S., Varma, Y., Fischbach, M.A., et al. (2014). Diet rapidly and reproducibly alters the human gut microbiome. *Nature* **505**, 559–563.
- Diraison, F., Moulin, P., and Beylot, M. (2003). Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. *Diabetes Metab.* **29**, 478–485.
- Diraison, F., Pachiaudi, C., and Beylot, M. (1996). In vivo measurement of plasma cholesterol and fatty acid synthesis with deuterated water: determination of the average number of deuterium atoms incorporated. *Metabolism* **45**, 817–821.
- Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., and Parks, E.J. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *J. Clin. Invest.* **115**, 1343–1351.
- Ducker, G.S., and Rabinowitz, J.D. (2017). One-carbon metabolism in health and disease. *Cell Metab.* **25**, 27–42.
- Duncan, S.H., Belenguer, A., Holtrop, G., Johnstone, A.M., Flint, H.J., and Lobley, G.E. (2007). Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. *Appl. Environ. Microbiol.* **73**, 1073–1078.
- Dushay, J., Chui, P.C., Gopalakrishnan, G.S., Varela-Rey, M., Crawley, M., Fisher, F.M., Badman, M.K., Martinez-Chantar, M.L., and Maratos-Flier, E. (2010). Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. *Gastroenterology* **139**, 456–463.
- Fabbrini, E., Sullivan, S., and Klein, S. (2010). Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* **51**, 679–689.
- Foster, G.D., Wyatt, H.R., Hill, J.O., McGuckin, B.G., Brill, C., Mohammed, B.S., Szapary, P.O., Rader, D.J., Edman, J.S., and Klein, S. (2003). A randomized trial of a low-carbohydrate diet for obesity. *N. Engl. J. Med.* **348**, 2082–2090.
- Gaggini, M., Morelli, M., Buzzigoli, E., DeFronzo, R.A., Bugianesi, E., and Gastaldelli, A. (2013). Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. *Nutrients* **5**, 1544–1560.
- Gambino, R., Musso, G., and Cassader, M. (2011). Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. *Antioxid. Redox Signal.* **15**, 1325–1365.
- Ginsberg, H.N., Le, N.A., Goldberg, I.J., Gibson, J.C., Rubinstein, A., Wang-Iverson, P., Norum, R., and Brown, W.V. (1986). Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. *J. Clin. Invest.* **78**, 1287–1295.
- Haas, J.T., Francque, S., and Staels, B. (2016). Pathophysiology and mechanisms of nonalcoholic fatty liver disease. *Annu. Rev. Physiol.* **78**, 181–205.
- Halsted, C.H., Villanueva, J.A., Devlin, A.M., Niemela, O., Parkkila, S., Garrow, T.A., Wallock, L.M., Shigenaga, M.K., Melnyk, S., and James, S.J. (2002). Folate deficiency disturbs hepatic methionine metabolism and promotes liver injury in the ethanol-fed micropig. *Proc. Natl. Acad. Sci. USA* **99**, 10072–10077.
- Hirsch, S., Poniachick, J., Avendano, M., Csendes, A., Burdiles, P., Smok, G., Diaz, J.C., and de la Maza, M.P. (2005). Serum folate and homocysteine levels in obese females with non-alcoholic fatty liver. *Nutrition* **21**, 137–141.
- Hong, S., Moreno-Navarrete, J.M., Wei, X., Kikukawa, Y., Tzameli, I., Prasad, D., Lee, Y., Asara, J.M., Fernandez-Real, J.M., Maratos-Flier, E., et al. (2015). Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. *Nat. Med.* **21**, 887–894.
- Kanehisa, M., and Goto, S. (2000). KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* **28**, 27–30.
- Karlsson, F.H., Nookae, I., and Nielsen, J. (2014). Metagenomic data utilization and analysis (MEDUSA) and construction of a global gut microbial gene catalogue. *PLoS Comput. Biol.* **10**, e1003706.
- Kekwick, A., and Pawan, G.L. (1956). Calorie intake in relation to body-weight changes in the obese. *Lancet* **271**, 155–161.
- Kelley, B., Totter, J.R., and Day, P.L. (1950). The lipotropic effect of folic acid on rats receiving various purified diets. *J. Biol. Chem.* **187**, 529–535.
- Keogh, J.B., Brinkworth, G.D., Noakes, M., Belobajdic, D.P., Buckley, J.D., and Clifton, P.M. (2008). Effects of weight loss from a very-low-carbohydrate diet on endothelial function and markers of cardiovascular disease risk in subjects with abdominal obesity. *Am. J. Clin. Nutr.* **87**, 567–576.
- Kersten, S. (2014). Integrated physiology and systems biology of PPARalpha. *Mol. Metab.* **3**, 354–371.
- Kim, T.H., Yang, J., Darling, P.B., and O'Connor, D.L. (2004). A large pool of available folate exists in the large intestine of human infants and piglets. *J. Nutr.* **134**, 1389–1394.
- Kindt, R., and Coe, R. (2005). Tree Diversity Analysis. A Manual and Software for Common Statistical Methods for Ecological and Biodiversity Studies (World Agroforestry Centre).
- Kolb, A.F., and Petrie, L. (2013). Folate deficiency enhances the inflammatory response of macrophages. *Mol. Immunol.* **54**, 164–172.
- Korem, T., Zeevi, D., Suez, J., Weinberger, A., Avnit-Sagi, T., Pompan-Lotan, M., Matot, E., Jona, G., Harmelin, A., Cohen, N., et al. (2015). Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. *Science* **349**, 1101–1106.
- Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L.M., Lundbom, N., Rissanen, A., Ridderstrale, M., Groop, L., et al. (2009). Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. *Gastroenterology* **137**, 865–872.
- Laeger, T., Henagan, T.M., Albarado, D.C., Redman, L.M., Bray, G.A., Noland, R.C., Munzberg, H., Hutson, S.M., Gettys, T.W., Schwartz, M.W., et al. (2014). FGF21 is an endocrine signal of protein restriction. *J. Clin. Invest.* **124**, 3913–3922.
- Le Roy, T., Llopis, M., Lepage, P., Bruneau, A., Rabot, S., Bevilacqua, C., Martin, P., Philippe, C., Walker, F., Bado, A., et al. (2013). Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. *Gut* **62**, 1787–1794.
- LeBlanc, J.G., Laino, J.E., del Valle, M.J., Vannini, V., van Sinderen, D., Taranto, M.P., de Valdez, G.F., de Giori, G.S., and Sesma, F. (2011). B-group vitamin production by lactic acid bacteria—current knowledge and potential applications. *J. Appl. Microbiol.* **111**, 1297–1309.
- Lee, S., Zhang, C., Kilicarslan, M., Piening, B.D., Bjornson, E., Hallstrom, B.M., Groen, A.K., Ferrannini, E., Laakso, M., Snyder, M., et al. (2016). Integrated network analysis reveals an association between plasma mannose levels and insulin resistance. *Cell Metab.* **24**, 172–184.
- Leung, C., Rivera, L., Furness, J.B., and Angus, P.W. (2016). The role of the gut microbiota in NAFLD. *Nat. Rev. Gastroenterol. Hepatol.* **13**, 412–425.
- Lewis, G.F., Carpenterier, A., Adeli, K., and Giacca, A. (2002). Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. *Endocr. Rev.* **23**, 201–229.
- Li, H., Fang, Q., Gao, F., Fan, J., Zhou, J., Wang, X., Zhang, H., Pan, X., Bao, Y., Xiang, K., et al. (2010). Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. *J. Hepatol.* **53**, 934–940.
- Li, H., Zhang, J., and Jia, W. (2013). Fibroblast growth factor 21: a novel metabolic regulator from pharmacology to physiology. *Front. Med.* **7**, 25–30.
- Lips, M.A., de Groot, G.H., Berends, F.J., Wiezer, R., van Wagenveld, B.A., Swank, D.J., Luijten, A., van Dijk, K.W., Pijl, H., Jansen, P.L., et al. (2014). Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects. *Clin. Endocrinol. (Oxf.)* **81**, 862–870.

- Lofgren, L., Forsberg, G.B., and Stahlman, M. (2016). The BUME method: a new rapid and simple chloroform-free method for total lipid extraction of animal tissue. *Sci. Rep.* 6, 27688.
- Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., and Loria, P. (2015). Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. *Dig. Liver Dis.* 47, 181–190.
- Loomba, R., Seguritan, V., Li, W., Long, T., Klitgord, N., Bhatt, A., Dulai, P.S., Caussy, C., Bettencourt, R., Highlander, S.K., et al. (2017). Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. *Cell Metab.* 25, 1054–1062.e5.
- Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* 15, 550.
- Lundbom, J., Hakkarainen, A., Soderlund, S., Westerbacka, J., Lundbom, N., and Taskinen, M.R. (2011). Long-TE 1H MRS suggests that liver fat is more saturated than subcutaneous and visceral fat. *NMR Biomed.* 24, 238–245.
- Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Nookae, I., Jacobson, P., Walley, A.J., Froguel, P., Carlsson, L.M., Uhlen, M., et al. (2013). Integration of clinical data with a genome-scale metabolic model of the human adipocyte. *Mol. Syst. Biol.* 9, 649.
- Mardinoglu, A., Agren, R., Kampf, C., Asplund, A., Uhlen, M., and Nielsen, J. (2014). Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. *Nat. Commun.* 5, 3083.
- Mardinoglu, A., Bjornson, E., Zhang, C., Klevstig, M., Soderlund, S., Stahlman, M., Adiels, M., Hakkarainen, A., Lundbom, N., Kilicarslan, M., et al. (2017). Personal model-assisted identification of NAD<sup>+</sup> and glutathione metabolism as intervention target in NAFLD. *Mol. Syst. Biol.* 13, 916.
- Mardinoglu, A., Shoaei, S., Bergentall, M., Ghaffari, P., Zhang, C., Larsson, E., Backhed, F., and Nielsen, J. (2015). The gut microbiota modulates host amino acid and glutathione metabolism in mice. *Mol. Syst. Biol.* 11, 834.
- Marengo, A., Rosso, C., and Bugianesi, E. (2016). Liver cancer: connections with obesity, fatty liver, and cirrhosis. *Annu. Rev. Med.* 67, 103–117.
- McGarry, J.D., Mannaerts, G.P., and Foster, D.W. (1977). A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. *J. Clin. Invest.* 60, 265–270.
- McMurdie, P.J., and Holmes, S. (2013). phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS One* 8, e61217.
- Murphy, R.C., James, P.F., McAnoy, A.M., Krank, J., Duchoslav, E., and Barkley, R.M. (2007). Detection of the abundance of diacylglycerol and triacylglycerol molecular species in cells using neutral loss mass spectrometry. *Anal. Biochem.* 366, 59–70.
- Nguyen, D., Samson, S.L., Reddy, V.T., Gonzalez, E.V., and Sekhar, R.V. (2013). Impaired mitochondrial fatty acid oxidation and insulin resistance in aging: novel protective role of glutathione. *Aging Cell* 12, 415–425.
- Noakes, M., Keogh, J.B., Foster, P.R., and Clifton, P.M. (2005). Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. *Am. J. Clin. Nutr.* 81, 1298–1306.
- Nuttall, F.Q., and Gannon, M.C. (2006). The metabolic response to a high-protein, low-carbohydrate diet in men with type 2 diabetes mellitus. *Metabolism* 55, 243–251.
- Paredes-Turubiarte, G., Gonzalez-Chavez, A., Perez-Tamayo, R., Salazar-Vazquez, B.Y., Hernandez, V.S., Garibay-Nieto, N., Fragoso, J.M., and Escobedo, G. (2016). Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients. *Clin. Exp. Med.* 16, 193–202.
- Pawlak, M., Lefebvre, P., and Staels, B. (2015). Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. *J. Hepatol.* 62, 720–733.
- Petersen, K.F., Dufour, S., Savage, D.B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G.W., Befroy, D., Zemany, L., Kahn, B.B., et al. (2007). The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc. Natl. Acad. Sci. USA* 104, 12587–12594.
- Petersen, M.C., Vatner, D.F., and Shulman, G.I. (2017). Regulation of hepatic glucose metabolism in health and disease. *Nat. Rev. Endocrinol.* 13, 572–587.
- Pramfall, C., Pavides, M., Banerjee, R., McNeil, C.A., Neubauer, S., Karpe, F., and Hodson, L. (2015). Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men. *J. Clin. Endocrinol. Metab.* 100, 4425–4433.
- Price, N.D., Magis, A.T., Earls, J.C., Glusman, G., Levy, R., Lausted, C., McDonald, D.T., Kusebauch, U., Moss, C.L., Zhou, Y., et al. (2017). A wellness study of 108 individuals using personal, dense, dynamic data clouds. *Nat. Biotechnol.* 35, 747–756.
- Rinella, M.E., and Sanyal, A.J. (2016). Management of NAFLD: a stage-based approach. *Nat. Rev. Gastroenterol. Hepatol.* 13, 196–205.
- Rossi, M., Amaretti, A., and Raimondi, S. (2011). Folate production by probiotic bacteria. *Nutrients* 3, 118–134.
- Roza, A.M., and Shizgal, H.M. (1984). The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass. *Am. J. Clin. Nutr.* 40, 168–182.
- Sid, V., Siow, Y.L., and O, K. (2017). Role of folate in nonalcoholic fatty liver disease. *Can. J. Physiol. Pharmacol.* 95, 1141–1148.
- Sid, V., Wu, N., Sarna, L.K., Siow, Y.L., House, J.D., and O, K. (2015). Folic acid supplementation during high-fat diet feeding restores AMPK activation via an AMP-LKB1-dependent mechanism. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 309, R1215–R1225.
- Singh, A., Gautier, B., Shannon, C.P., Vacher, M., Rohart, F., Tebbutt, S.J., and Le Cao, K.-A. (2016). DIABLO - an integrative, multi-omics, multivariate method for multi-group classification. *bioRxiv*. <https://doi.org/10.1101/067611>.
- Solga, S., Alkhuraishe, A.R., Clark, J.M., Torbenson, M., Greenwald, A., Diehl, A.M., and Magnuson, T. (2004). Dietary composition and nonalcoholic fatty liver disease. *Dig. Dis. Sci.* 49, 1578–1583.
- Ståhlman, M., Davidsson, P., Kammet, I., Rosengren, B., Borén, J., Fagerberg, B., and Camejo, G. (2008). Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. *J. Lipid Res.* 49, 481–490.
- Stefan, N., Kantartzis, K., and Haring, H.U. (2008). Causes and metabolic consequences of fatty liver. *Endocr. Rev.* 29, 939–960.
- Strozzi, G.P., and Mogna, L. (2008). Quantification of folic acid in human feces after administration of *Bifidobacterium* probiotic strains. *J. Clin. Gastroenterol.* 42 (Suppl. 3 Pt 2), S179–S184.
- Sugahara, H., Odamaki, T., Hashikura, N., Abe, F., and Xiao, J.Z. (2015). Differences in folate production by *bifidobacteria* of different origins. *Biosci. Microbiota Food Health* 34, 87–93.
- Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G., and Barbui, C. (2016). Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. *J. Hepatol.* 65, 589–600.
- Taskinen, M.R., Kuusi, T., Helve, E., Nikkila, E.A., and Yki-Jarvinen, H. (1988). Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. *Arteriosclerosis* 8, 168–177.
- R Core Team. (2015). R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing).
- Tryndyak, V., de Conti, A., Kobets, T., Kutanzi, K., Koturbash, I., Han, T., Fuscoe, J.C., Latendresse, J.R., Melnyk, S., Shymonyak, S., et al. (2012). Interstrain differences in the severity of liver injury induced by a choline- and folate-deficient diet in mice are associated with dysregulation of genes involved in lipid metabolism. *FASEB J.* 26, 4592–4602.
- Wallner, S., and Schmitz, G. (2011). Plasmalogens the neglected regulatory and scavenging lipid species. *Chem. Phys. Lipids* 164, 573–589.
- Wang, Y., Viscarra, J., Kim, S.J., and Sul, H.S. (2015). Transcriptional regulation of hepatic lipogenesis. *Nat. Rev. Mol. Cell Biol.* 16, 678–689.
- Wichmann, A., Allahyar, A., Greiner, T.U., Plovier, H., Lundén, G.O., Larsson, T., Drucker, D.J., Delzenne, N.M., Cani, P.D., and Backhed, F. (2013). Microbial modulation of energy availability in the colon regulates intestinal transit. *Cell Host Microbe* 14, 582–590.

- Wieckowska, A., Papouchado, B.G., Li, Z., Lopez, R., Zein, N.N., and Feldstein, A.E. (2008). Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. *Am. J. Gastroenterol.* 103, 1372–1379.
- Witthöft, C.M., Forssén, K., Johannesson, L., and Jägerstad, M. (1999). Folates - food sources, analyses, retention and bioavailability. *Scand. J. Nutr.* 43, 138–146.
- Wu, G.D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.Y., Keilbaugh, S.A., Bewtra, M., Knights, D., Walters, W.A., Knight, R., et al. (2011). Linking long-term dietary patterns with gut microbial enterotypes. *Science* 334, 105–108.
- Wu, H., Esteve, E., Tremaroli, V., Khan, M.T., Caesar, R., Manneras-Holm, L., Stahlman, M., Olsson, L.M., Serino, M., Planas-Felix, M., et al. (2017). Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeutic effects of the drug. *Nat. Med.* 23, 850–858.
- Wu, H., Tremaroli, V., and Backhed, F. (2015). Linking microbiota to human diseases: a systems biology perspective. *Trends Endocrinol. Metab.* 26, 758–770.
- Wycherley, T.P., Brinkworth, G.D., Keogh, J.B., Noakes, M., Buckley, J.D., and Clifton, P.M. (2010). Long-term effects of weight loss with a very low carbohydrate and low fat diet on vascular function in overweight and obese patients. *J. Intern. Med.* 267, 452–461.
- Xia, M.F., Bian, H., Zhu, X.P., Yan, H.M., Chang, X.X., Zhang, L.S., Lin, H.D., Hu, X.Q., and Gao, X. (2017). Serum folic acid levels are associated with the presence and severity of liver steatosis in Chinese adults. *Clin. Nutr.* <https://doi.org/10.1016/j.clnu.2017.06.021>.
- Young, M.D., Wakefield, M.J., Smyth, G.K., and Oshlack, A. (2010). Gene ontology analysis for RNA-seq: accounting for selection bias. *Genome Biol.* 11, R14.
- Zhou, D., Pan, Q., Shen, F., Cao, H.X., Ding, W.J., Chen, Y.W., and Fan, J.G. (2017). Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. *Sci. Rep.* 7, 1529.

**STAR★METHODS****KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Proseek Multiplex Inflammation 196 $\times$ 96 array	Olink Bioscience	article 94300
Chemicals, Peptides, and Recombinant Proteins		
DNeasy Blood and Tissue kit	QIAGEN	Cat# 69506
Critical Commercial Assays		
FGF-21	R&D Systems	Cat# DF2100
IL-6	R&D Systems	Cat# D6050
TNF- $\alpha$	R&D Systems	Cat# DTA00C
Triglycerides	Thermo Fisher Scientific	TR22421
Cholesterol	Thermo Fisher Scientific	TR13421
Insulin	Thermo Fisher Scientific	KAQ1251
NEFA-HR(2) Assay	Wako	434-91795
$\beta$ -hydroxybutyrate	DiaSys Diagnostic Systems	1 3701 99 10 930
Folate	Roche Diagnostics USA	A98032
Genotyping PNPLA3 rs738409	TaqMan Applied Biosystems	ID: C_7241_10
Genotyping TM6SF2 rs58542926	TaqMan Applied Biosystems	ID: C_89463510_10
Deposited Data		
RNAseq liver data	NCBI Gene Expression Omnibus	GEO: GSE107650
Metagenomics data	Sequence Read Archive	SRA: PRJNA420817
Software and Algorithms		
jMRUI v3.0 software	jMRUI	<a href="http://www.jmrui.eu/license-and-download/jmrui-license/">http://www.jmrui.eu/license-and-download/jmrui-license/</a>
LCModel v6.3g software	LCModel	<a href="http://www.lcmodel.com/lcmodel.shtml">http://www.lcmodel.com/lcmodel.shtml</a>
DESeq2	bioconductor	<a href="http://bioconductor.org/packages/release/bioc/html/DESeq2.html">http://bioconductor.org/packages/release/bioc/html/DESeq2.html</a>
Phyloseq (1.19.1)	bioconductor	<a href="https://bioconductor.org/packages/release/bioc/html/phyloseq.html">https://bioconductor.org/packages/release/bioc/html/phyloseq.html</a>
Goseq	bioconductor	<a href="https://bioconductor.org/packages/release/bioc/html/goseq.html">https://bioconductor.org/packages/release/bioc/html/goseq.html</a>
visreg	R	<a href="https://cran.r-project.org/web/packages/visreg/index.html">https://cran.r-project.org/web/packages/visreg/index.html</a>
lme4 package	R	<a href="https://cran.r-project.org/web/packages/lme4/index.html">https://cran.r-project.org/web/packages/lme4/index.html</a>
GRCh38	Genome Reference Consortium	<a href="https://www.ncbi.nlm.nih.gov/grc/human">https://www.ncbi.nlm.nih.gov/grc/human</a>
mixDIABLO	mixOmics	<a href="http://mixomics.org/mixDIABLO/">http://mixomics.org/mixDIABLO/</a>

**CONTACT FOR REAGENT AND RESOURCE SHARING**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jan Borén ([jan.boren@wlab.gu.se](mailto:jan.boren@wlab.gu.se)).

**EXPERIMENTAL MODEL AND SUBJECT DETAILS****Clinical Study Design**

Ten middle-aged (54 $\pm$ 4 years) subjects (2 women, 8 men) with high liver fat were recruited to the first cohort in this study. All subjects had stable ( $\pm$ 5 kg) weight in the three months preceding enrollment.

The inclusion criteria were high liver fat (>5.5% measured by MRS), body mass index 27–40 kg/m<sup>2</sup>, negative viral hepatitis serology, transferrin saturation <40%, normal  $\alpha$ 1-antitrypsin and ceruloplasmin concentrations, negative autoimmune liver disease markers, negative pregnancy test for pre-menopausal women on enrollment, and no history of medication use associated with hepatic steatosis. The exclusion criteria were liver cirrhosis, portal hypertension, chronic liver disease other than NAFLD, including

alcoholic liver disease as defined by daily alcohol intake of >40 g (men) and >20 g (women), respectively, significant endocrine disease including diabetes, any medication acting on nuclear hormone receptors or inducing CYP P450, self-administration of supplements other than calcium, any significant cardiovascular co-morbidity, history of non-compliance, and genetic variations in the two main genetic determinants of liver fat accumulation: *PNPLA3* (homozygous for I148M) or *TM6SF2* (homozygous or heterozygous for E167K).

Participants in the first cohort followed an isocaloric low-carbohydrate diet with increased protein content for 14 days and came to the study center on days 0, 1, 3, 4, 7, 10 and 14 of the diet after an overnight fast. At each of these visits, subjects were weighed, blood samples were taken and liver fat was measured (by MRS). Fecal samples were collected on days 0, 1, 3, 7 and 14. The study design with time-points for the different analyses performed is shown in Figure 1B.

To obtain liver biopsies from obese individuals with high liver fat before and after the low-carbohydrate diet with increased protein content, we recruited a second cohort (5 men, 2 women; mean age  $47.3 \pm 14.6$  years). These subjects were mildly obese ( $BMI 32.1 \pm 3.8 \text{ kg/m}^2$ ) with ultrasound-verified fatty liver (but without diabetes or any medication) who underwent a Menghini liver biopsy for the diagnosis of NASH. Those individuals from whom we obtained biopsies >4 cm (of which 2 cm was used for histological confirmation of NAFLD/NASH with no advanced fibrosis; see Table S4) were asked to agree to a second biopsy within two weeks and to follow the identical low-carbohydrate diet with increased protein content as the first cohort for 7 days until the morning before the second biopsy. Blood samples were taken from the participants on the same day as their biopsies.

The study was performed in accordance with the Declaration of Helsinki and it was approved by the Helsinki University Central Hospital Ethics Committee (for the first cohort) and the Ethics Committee at the University of Gothenburg (liver biopsy cohort). Each subject gave written informed consent before participation in the study. A CONSORT flow diagram for the study is shown in Figure S7.

### Isocaloric Carbohydrate-Restricted Diet

Subjects in the first cohort were instructed to follow an isocaloric low-carbohydrate diet with increased protein content (providing a mean of 3114.6 kcal energy per day) for 14 days. Each subject's energy requirement was estimated (using the Harris Benedict equation) from the basal metabolic rate (Roza and Shizgal, 1984), which was multiplied by 1.5 corresponding to the subject's activity level. The study diet provided approximately 4% energy from carbohydrate, 72% energy from fat and 24% energy from protein whereas the corresponding macronutrient composition in the baseline diet was 40%, 42% and 18%, respectively (Figure 1A). The carbohydrate content of the diet was restricted to 23–30 g per day.

To ensure compliance with the diet, subjects underwent a teaching session and had daily contact with an experienced dietitian. Study subjects were asked to keep dietary records for 3 days beforehand to record the macronutrient content of the baseline diet.

All meals and snacks were pre-prepared in a metabolic kitchen and weighed and delivered to the subjects twice a week during the 14-day study period. The meals were frozen and the snacks and vegetables were fresh. The subjects were permitted to consume calorie-free beverages and sweeteners. The dietitian also instructed the participants to increase their daily energy intake by 200 kcal from macadamia nuts whenever their weight decreased between two study days by more than 0.2 kg. During the study, all study subjects filled in a checklist of the meal consumed to keep track of meals eaten. The actual macronutrient intake during the low-carbohydrate diet with increased protein content was calculated based on the checklists recorded by the subjects. The dietitian contacted the participants daily (by phone or email) to verify adherence to the meal plan and check weight stability (measured by home scales).

### Influence of Gender

The first cohort consisted of ten obese ( $BMI 34.1 \pm 1.2 \text{ kg/m}^2$ ) middle-aged ( $54 \pm 4$  years) subjects (2 women, 8 men) with high liver fat. The second cohort consisted of seven obese ( $BMI 32.1 \pm 3.8 \text{ kg/m}^2$ ) middle-aged ( $47 \pm 15$  years) subjects (2 women, 5 men) with high liver fat. All subjects were analyzed as their own control, during and after the diet intervention. Subgroup analysis did not reveal differences between women and men in their responses of liver fat content during the diet intervention.

## METHOD DETAILS

### Genotyping of *PNPLA3* and *TM6SF2* Variants

DNA was extracted from whole blood using DNeasy Blood and Tissue kit according to the manufacturer's instructions. *PNPLA3* rs738409 and *TM6SF2* rs58542926 variants were genotyped by 5'-nuclease Taqman Assays. Primers and probes (FAM and VIC labelled) were directly supplied by ThermoFisher Scientific (TaqMan Applied Biosystems, Assay ID: C\_7241\_10 and C\_89463510\_10 for *PNPLA3* rs738409 and *TM6SF2* rs58542926, respectively). Post-PCR allelic discrimination was performed on a CFX384 Real-Time System (Bio-Rad) by measuring allele-specific fluorescence. For both variants, genotyping was performed in triplicate with concordance between replicates and success rate of 100%.

### Body Composition, Liver Fat and Liver Volume

Body composition of the first cohort was determined using a Tanita MC-980 MA body composition analyzer at baseline and on day 14. Liver fat and liver volume were assessed by MRS and magnetic resonance imaging (Bian et al., 2014) using a clinical 1.5 imager (Avantofit, Siemens, Erlangen, Germany). For determination of liver fat content, PRESS localization technique was used to collect

$25 \times 25 \times 25 \text{ mm}^3$  spectra with five different echo times (TE): 30, 50, 80, 135 and 200 ms with 4, 4, 4, 8 and 64 number of averages, respectively. Acquisition was triggered to end-expiration (TR > 3000 ms). Intensities of water and methylene resonances were assessed using LCModel v6.3g software. The apparent T2 relaxation times of methylene and water resonances did not change during the study (Table S1). For each individual experiment, the apparent T2 of water and methylene was determined by monoexponential fit to five TEs. T2 relaxation effects on intensities were corrected, and liver fat content was calculated as the ratio methylene:(methylene+water) and further converted to mass fractions as described (Kotronen et al., 2009). Unsaturation indices were determined from 200 ms spectra using jMRUI v3.0 software (Lundbom et al., 2011).

### Measurement of Hepatic DNL

DNL was analyzed as described previously (Diraison et al., 1996). Absolute DNL [i.e., the contribution of DNL to triglycerides within plasma very low-density lipoproteins (VLDL-TG)] was calculated by multiplying the relative contribution of newly synthesized palmitate from DNL to VLDL-TG by the concentration of triglycerides in VLDL (Pramfalk et al., 2015). One subject was excluded from the analysis of DNL for technical reasons.

### Lipoproteins and Biochemical Analyses

In the first cohort, lipoprotein fractions were separated as described previously (Taskinen et al., 1988). Serum VLDL from the second cohort was isolated by ultracentrifugation using deuterium oxide as described previously (Ståhlman et al., 2008). Plasma concentrations of triglyceride, cholesterol, NEFA,  $\beta$ -hydroxybutyrate, glucose and serum insulin were analyzed using a Konelab 60i analyzer (Thermo Fisher Scientific). Plasma levels of FGF21, IL-6, TNF- $\alpha$  and apoC-III were measured by ELISA (R&D Systems, Minneapolis, USA). Other inflammatory protein biomarkers were analyzed using the Proseek Multiplex Inflammation I $^{66 \times 66}$  array (Olink Bioscience, Uppsala, Sweden). Serum folate was measured using a chemiluminescent immunoassay (Roche Diagnostics USA).

### Fecal Genomic DNA and Genome Sequencing

Fecal genomic DNA was extracted from 100 mg of frozen stools from the first cohort using the QIAamp DNA mini stool kit (Qiagen, Courtaboeuf, France) following repeated bead-beating (6500 r.p.m., 3 x 30 s). The DNA was extracted from 48 fecal samples, obtained from the 10 participants at 5 different time points during the study (2 fecal samples from day 1 were not obtained). DNA fragments of approximately 300 bp were sequenced on an Illumina NextSeq 500 instrument (150 bp; paired-end) at the Genomics Core Facility, Sahlgrenska Academy, University of Gothenburg.

### Metagenomics Analyses

We obtained a total of 151 Gb of raw paired-end reads. The taxonomic and KO composition was obtained by using an updated version of the MEDUSA pipeline (Karlsson et al., 2014), as described before (Wu et al., 2017). The mean mapping rates for the genome and gene catalogues were 43.1% and 72.6%, respectively (Table S2). The obtained taxonomic composition and KO profile matrix were further analyzed by DESeq2 package (Love et al., 2014). Pathway enrichment analyses are based on KEGG annotation (Kanehisa and Goto, 2000) and hypergeometric test using gosseq (Young et al., 2010). The beta diversity and PCoA analysis were calculated based on the relative abundance of all significant strains (further transformed by square root to reduce the influence of dominant KOs as suggested previously (Kindt and Coe, 2005) using phyloseq (version 1.19.1) (McMurdie and Holmes, 2013).

### Measurement of Fecal SCFAs and Folate

Fecal SCFAs were measured using gas chromatography coupled to mass spectrometry detection (GC-MS) as described previously (Wichmann et al., 2013). In brief, approximately 50–250 mg of feces was mixed with internal standards, added to glass vials and freeze dried. All samples were then acidified with HCl, and SCFAs were extracted with two rounds of diethyl ether extraction. The organic supernatant was collected, the derivatization agent N-tert-butyldimethylsilyl- N-methyltrifluoroacetamide (Sigma-Aldrich, Stockholm, Sweden) was added, and samples were incubated overnight. SCFAs were quantified with a 7090A gas chromatograph coupled to a 5975C mass spectrometer (Agilent Technologies 5975C, Santa Clara, CA). SCFA standards were obtained from Sigma-Aldrich (Stockholm, Sweden).

For folate measurements, approximately 100 mg of fecal sample was transferred to pre-weighed Sarstedt tubes along with six ceramic beads. 500  $\mu\text{L}$  methanol:water [80:20] containing 20 mM ammonium acetate, 0.1% ascorbic acid and 100 nM of the internal standard 5-methyl-THF- $^{13}\text{C}_1,\text{d}_3$  (Toronto Research Chemicals, Downsview, ON, Canada) was added and the samples were homogenized for 10 min at 25 Hz using a TissueLyser instrument (Qiagen Nordic, Copenhagen, Denmark). The samples were then centrifuged at 20,000g for 10 min and 300  $\mu\text{L}$  of supernatant was transferred to glass vials and evaporated under a stream of nitrogen. The dried samples were reconstituted in 150  $\mu\text{L}$  of injection solvent (methanol:water [10:90] + 0.1% HCl) and vortexed for 5 min at 1500 rpm. The sample were added to an OSTRO 96-well plate (Waters, Milford, MA) and eluted under positive pressure into the 96-well collection plate.

The samples were then injected into a Waters Acquity UPLC system equipped with a Waters BEH Phenyl column (2.1 x 100 mm; 1.7  $\mu\text{m}$  particle size). Column temperature was maintained at 30°C and the flow rate was 400  $\mu\text{L}/\text{min}$ . The temperature of the auto sampler was set at 12°C. The mobile phases consisted of water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B). Gradient elution was performed using a linear gradient from 1–15% B over 3 min. The gradient was then increased linearly to 99% B over 4 min. After 0.5 min of isocratic elution the gradient returned to 1% B and held for 2.5 min for a total runtime of 10 min.

The folates were detected using a Xevo TQ-XS (Waters, Milford, MA) using positive electrospray. Fine tune of the mass spectrometer for each metabolite was performed. After optimization the ion source parameters were: Capillary: 1.00 kV, Desolvation temperature 500°C, Desolvation gas flow 1000 L/h, Cone gas flow 150 L/h, Nebulizer gas flow 7.0 L/h, Cone voltage 20 V, Collision energy 20 eV. For each analyte the most intense precursor/product ion transition was selected. Consequently, the MRM transitions used were: Folic acid  $m/z$  442.2 → 295.2, 5-methyl-THF  $m/z$  460.2 → 313.2, 5-methyl-THF- $^{13}\text{C}_1,\text{d}_3$   $m/z$  464.2 → 317.2. Dwell time was 44 ms for all analytes.

### Untargeted Metabolomics Analyses

Untargeted metabolomic profiling of plasma was performed by Metabolon (Durham, NC), as previously described (Lee et al., 2016). Samples were prepared using the automated MicroLab STAR system from Hamilton Company. A recovery standard was added before the first step in the extraction process for quality control purposes. Sample preparation was conducted using aqueous methanol extraction process to remove the protein fraction while allowing maximum recovery of small molecules. The resulting extract was divided into four fractions: one for analysis by UPLC/MS/MS (positive mode), one for UPLC/MS/MS (negative mode), one for GC/MS, and one for backup. Samples were placed briefly on a TurboVap (Zymark) to remove the organic solvent. Each sample was then frozen and dried under vacuum. Samples were then prepared for the appropriate instrument (either UPLC/MS/MS or GC/MS).

### Liver Lipid Analysis

Liver biopsies from the second cohort were collected in tubes with RNAlater (Qiagen, Hilden, Germany) and stored at -80°C. Lipids from liver biopsies were extracted as previously described (Lofgren et al., 2016). Lipid extracts were diluted in chloroform:methanol [1:2] containing 5 mM ammonium acetate and infused into a QTRAP 5500 mass spectrometer (Sciex, Concord, Canada) using a NanoMate Triversa (Advion Biosciences, Ithaca, NY). Phosphatidylcholines and triglycerides were detected in positive mode using precursor ion scanning and neutral loss scanning as previously described (Brugger et al., 1997; Murphy et al., 2007). Quantification was made against internal standards added during the extraction.

### Transcript Profiling of Liver Biopsies

Total RNA was extracted from the liver biopsies using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, and used in the subsequent mRNA sample preparation for sequencing using Illumina HiSeq 2500 systems with the standard Illumina RNA-seq protocol. The RNAseq was performed at GATC Biotech AG [project number NG-10969] (Konstanz, Germany). Gene abundance (in both raw counts and transcripts per million) was quantified using the kallisto pipeline (Bray et al., 2016) based on human genome assembly version GRCh38. The DESeq2 package (Anders and Huber, 2010) was used to identify differentially expressed genes.

### Model Simulation

A previously established genome-scale metabolic model for liver, *iHepatocyte2322* (Mardinoglu et al., 2014), was used to investigate the metabolic shifts in response to the diet. The substrate uptake of the model is constrained partly based on a previous study (Mardinoglu et al., 2017) and the fluxes are provided in Table S6. To investigate the flux change in response to the diet, both transcriptomic and metabolomic changes were integrated as constraints into the model using a previously developed method, RMetD (Mardinoglu et al., 2015). The flux distribution was calculated based on the average of 10,000 random sampled fluxes as previously described (Mardinoglu et al., 2013).

## QUANTIFICATION AND STATISTICAL ANALYSIS

### Statistical Analysis

All statistical analyses were performed in the R environment (R Core Team, 2015). The Wald test or the Likelihood Ratio Test was used to analyze differential abundances for all count data (for metagenomics and liver transcriptomics) depending on whether the dataset contains samples collected at two time points or at more than two time points from each individual. One-way ANOVA with repeated measurements was used for all other longitudinal datasets (for phenomics and metabolomics). Otherwise, two-tailed Wilcoxon rank-sum tests or Wilcoxon signed-rank tests were used throughout the study, depending on whether the samples were paired. The linear mixed effect model was built using lme4 package (Bates et al., 2015) in which liver fat adjusted for BMI was entered as a response variable whereas serum folate adjusted for BMI was entered for fixed effect and individual IDs as random effect. The model was visualized by visreg (Breheny and Burchett, 2016) and conditional and marginal coefficients of the model were determined using MuMIn (Bartoń, 2016). The residual plot and quantile-quantile plot are shown in Figure S6. The multivariate analysis and integration of phenomics, metagenomics, and metabolomics are based on mixDIABLO (Singh et al., 2016). The Spearman's rank-order correlation was used to determine the strength and direction of the monotonic relationships between two variables unless strong collinearity was observed, in which case the Pearson product-moment correlation was calculated. Raw P values were adjusted by the Benjamini-Hochberg method (Benjamini and Hochberg, 1995) with a false discovery rate of 5%, unless indicated otherwise. Data are shown as mean±s.e.m. unless otherwise indicated.

**DATA AND SOFTWARE AVAILABILITY****Datasets Generated and Deposited**

Metagenomics data from the first cohort were deposited at Sequence Read Archive with accession number SRA: PRJNA420817. RNA-seq raw and processed files from double liver needle biopsies taken before and after one-week diet intervention from the second cohort were deposited at NCBI Gene Expression Omnibus with accession number GEO: GSE107650.


**ADDITIONAL RESOURCES**

The clinical trial was registered at [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT02558530) with identifier: NCT02558530; <https://clinicaltrials.gov/ct2/show/NCT02558530>


**Supplemental Information**

**An Integrated Understanding of the Rapid  
Metabolic Benefits of a Carbohydrate-Restricted  
Diet on Hepatic Steatosis in Humans**


**Adil Mardinoglu, Hao Wu, Elias Bjornson, Cheng Zhang, Antti Hakkarainen, Sari M. Räsänen, Sunjae Lee, Rosellina M. Mancina, Mattias Bergentall, Kirsi H. Pietiläinen, Sanni Söderlund, Niina Matikainen, Marcus Ståhlman, Per-Olof Bergh, Martin Adiels, Brian D. Piening, Marit Granér, Nina Lundbom, Kevin J. Williams, Stefano Romeo, Jens Nielsen, Michael Snyder, Mathias Uhlén, Göran Bergström, Rosie Perkins, Hanns-Ulrich Marschall, Fredrik Bäckhed, Marja-Riitta Taskinen, and Jan Borén**




**Figure S1.** Box plots (with median) showing liver volume at baseline (D0) and after 14 days of the carbohydrate-restricted diet (D14) in the first cohort ( $n = 10$ ). Related to Figure 1 and Table S1. \*\* $P < 0.01$  (Wilcoxon signed-rank test).




**Figure S2. Pairwise Pearson correlations between delta changes (day 14 versus day 0 of the carbohydrate-restricted diet) for liver fat, VLDL-triglycerides (TG), apoCIII, DNL, and  $\beta$ -hydroxybutyrate in the first cohort ( $n = 8$ ).** Related to Figure 1 and Table S1. Boxes in the lower triangle (which show correlation plots) are mirrored by boxes in the upper triangles (which present the corresponding correlation coefficient and  $P$  value). Note the variables are color coded (e.g. yellow liver fat, blue border for VLDL-TG). One individual with an extreme DNL value (red circle) and one individual without a DNL measurement were not included in this analysis. Arrows indicate how to read the correlation matrix (in this case the correlation between liver fat and  $\beta$ -hydroxybutyrate). Solid arrows show the plot, and dashed lines the correlation coefficient and  $P$  value.




**Figure S3. MA plot for all KOs annotated from metagenomics data in the first cohort at day 14 versus day 0 of the carbohydrate-restricted diet ( $n = 10$ ).** Related to Figure 3 and Table S2. KOs that are significantly upregulated and downregulated at day 14 are shown in red and blue, respectively. FDR < 0.05 (likelihood ratio test).




**Figure S4. Box plots (with median) showing concentrations of fecal folate at baseline (D0) and after 3 days of the diet (D3) in the first cohort ( $n = 7$ ). Related to Figure 3. Note that only fecal samples obtained at these time points were used here because many fecal samples were missing due to earlier analyses (metagenomics and SCFAs measurements). One-tailed Wilcoxon signed-rank test.**



**Figure S5. Heatmap plot showing metabolites that significantly changed across the study period in serum from the first cohort ( $n = 10$ ).** Related to Figure 4 and Table S3. D, day. Pathways highlighted in pink background are upregulated whereas the ones with green background are downregulated. FDR < 0.05 (one-way ANOVA with repeated measurements).



**Figure S6. Residual plot and quantile-quantile (Q-Q) plot for evaluation of the linear mixed-effect model.** Related to Figure 4B.



**Figure S7. CONSORT flow diagram for the study.** Related to Figure 1B.